Bio China 2012
 

Follow Us

Facebook Twitter YouTube LinkedIn
 

Visit bio.org | Read all BIO Business Links

 

7/10/13

Chinese In-Licensing Continues to Strengthen

Chinese companies are eager to collaborate with their ex-China counterparts, and in-licensing agreements are out pacing other forms of biotech deal-making in 2013. In fact, the number of in-licensing deals announced so far this year is more than the combined number of 2012 deals in out-licensing, JV/Alliance and M&A, according to BIO’s Industry Analysis research and GBI.

This deal-making momentum bodes well for small and medium-sized biotech companies that have early-stage compounds under development in the West, but lack the bandwidth, capital or regulatory experience to develop them for the Chinese market. The past year has seen a host of Chinese companies in-license compounds from U.S. and European biotech companies across a wide range of therapeutic areas.

Notable in-licensing deals over the past year include OmniRat’s licensing deal with WuXi PharmaTech, MediStem and Superview’s deal to develop antibodies that affect stem cells and ArGEN-X’s licensing of a cancer and anti-inflammatory mAb to RuiYi. In early 2013, DYAX licensed Kalbitor®, a treatment for hereditary angioedema, to Lee’s Pharma Subsidiary. And, in April, Hengrui licensed X-Body's ophthalmic therapeutic antibody generated from X-Body’s antibody platform for Age-related Macular Degeneration Antibody (AMD).

Is your organization positioned to showcase your product and services and initiate deals in this burgeoning market?  The 2013 BIO® Convention in China, taking place November 11-13 in Beijing, is the best venue for cross-border business development, networking, partnering and education opportunities. Let BIO connect you with potential Chinese partners efficiently and economically. Register now for the BIO® Convention in China to gain access to the BIO One-on-One Partnering™ system and start scouting for your next deal!

Recent deals involving Chinese companies:

Date

Recent Alliance/Licensing Headlines

May-13

Zhejiang Huahai gets exclusive rights to four biosimilars from Oncobiologics (USA)

Apr-13

Hengrui licenses X-Body's ophthalmic therapeutic antibody

Mar-13

Fosun Pharma will sell Saladax's (USA) MyCare cancer assays in China

Feb-13

Lee’s Pharma Subsidiary In-Licenses DYAX Drug (USA)

Feb-13

China’s Grandhope Biotech In-licenses Stem Cell Technology from Orthocell (Australia)

Jan-13

SciClone continues relationship with Sanofi (Europe) surrounding four marketed therapies

Jan-13

Huapont Pharma and Yes Biotech (Canada) to Partner on Psoriasis Ointment

Jan-13

China GrandPharma In-Licenses Acetium Capsules from Biohit (Europe)

Jan-13

Hisun and Celsion enter into development and licensing option agreement

Dec-12

Techpool In-Licenses China Rights to Bone Cancer Drug from Roche (Europe)

Nov-12

Sihuan Pharma In-Licenses Two CCV Products from NeuroVive (Europe)

Oct-12

Hubei Qianjiang Pharma In-licenses Two Drugs from TNI BioTech (USA)

Oct-12

RuiYi In-Licenses Cancer/Anti-Inflammatory mAb from ArGEN-X (Europe)

Oct-12

MediStem and Superview to Develop Antibodies that Affect Stem Cells

Sep-12

WuXi PharmaTech Licenses OMT’s (USA) OmniRat to Aid Biologic Drug Discovery

The 3rd annual BIO Convention in China will bring together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities with China's emerging biotech and rapidly expanding pharmaceutical sectors. For more information or to register, visit bio.org/biochina

Add biopartnering@bio.org to your contacts to ensure email delivery.
Not displaying correctly? View this email in a browser.
If you received this message from a colleague, or would like to
receive information on our full spectrum of events, please click here.